Cargando…
Emerging Role of Metabolomics in Ovarian Cancer Diagnosis
Ovarian cancer is considered a silent killer due to the lack of clear symptoms and efficient diagnostic tools that often lead to late diagnoses. Over recent years, the impelling need for proficient biomarkers has led researchers to consider metabolomics, an emerging omics science that deals with ana...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7603269/ https://www.ncbi.nlm.nih.gov/pubmed/33086611 http://dx.doi.org/10.3390/metabo10100419 |
_version_ | 1783603882030530560 |
---|---|
author | Saorin, Asia Di Gregorio, Emanuela Miolo, Gianmaria Steffan, Agostino Corona, Giuseppe |
author_facet | Saorin, Asia Di Gregorio, Emanuela Miolo, Gianmaria Steffan, Agostino Corona, Giuseppe |
author_sort | Saorin, Asia |
collection | PubMed |
description | Ovarian cancer is considered a silent killer due to the lack of clear symptoms and efficient diagnostic tools that often lead to late diagnoses. Over recent years, the impelling need for proficient biomarkers has led researchers to consider metabolomics, an emerging omics science that deals with analyses of the entire set of small-molecules (≤1.5 kDa) present in biological systems. Metabolomics profiles, as a mirror of tumor–host interactions, have been found to be useful for the analysis and identification of specific cancer phenotypes. Cancer may cause significant metabolic alterations to sustain its growth, and metabolomics may highlight this, making it possible to detect cancer in an early phase of development. In the last decade, metabolomics has been widely applied to identify different metabolic signatures to improve ovarian cancer diagnosis. The aim of this review is to update the current status of the metabolomics research for the discovery of new diagnostic metabolomic biomarkers for ovarian cancer. The most promising metabolic alterations are discussed in view of their potential biological implications, underlying the issues that limit their effective clinical translation into ovarian cancer diagnostic tools. |
format | Online Article Text |
id | pubmed-7603269 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-76032692020-11-01 Emerging Role of Metabolomics in Ovarian Cancer Diagnosis Saorin, Asia Di Gregorio, Emanuela Miolo, Gianmaria Steffan, Agostino Corona, Giuseppe Metabolites Review Ovarian cancer is considered a silent killer due to the lack of clear symptoms and efficient diagnostic tools that often lead to late diagnoses. Over recent years, the impelling need for proficient biomarkers has led researchers to consider metabolomics, an emerging omics science that deals with analyses of the entire set of small-molecules (≤1.5 kDa) present in biological systems. Metabolomics profiles, as a mirror of tumor–host interactions, have been found to be useful for the analysis and identification of specific cancer phenotypes. Cancer may cause significant metabolic alterations to sustain its growth, and metabolomics may highlight this, making it possible to detect cancer in an early phase of development. In the last decade, metabolomics has been widely applied to identify different metabolic signatures to improve ovarian cancer diagnosis. The aim of this review is to update the current status of the metabolomics research for the discovery of new diagnostic metabolomic biomarkers for ovarian cancer. The most promising metabolic alterations are discussed in view of their potential biological implications, underlying the issues that limit their effective clinical translation into ovarian cancer diagnostic tools. MDPI 2020-10-19 /pmc/articles/PMC7603269/ /pubmed/33086611 http://dx.doi.org/10.3390/metabo10100419 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Saorin, Asia Di Gregorio, Emanuela Miolo, Gianmaria Steffan, Agostino Corona, Giuseppe Emerging Role of Metabolomics in Ovarian Cancer Diagnosis |
title | Emerging Role of Metabolomics in Ovarian Cancer Diagnosis |
title_full | Emerging Role of Metabolomics in Ovarian Cancer Diagnosis |
title_fullStr | Emerging Role of Metabolomics in Ovarian Cancer Diagnosis |
title_full_unstemmed | Emerging Role of Metabolomics in Ovarian Cancer Diagnosis |
title_short | Emerging Role of Metabolomics in Ovarian Cancer Diagnosis |
title_sort | emerging role of metabolomics in ovarian cancer diagnosis |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7603269/ https://www.ncbi.nlm.nih.gov/pubmed/33086611 http://dx.doi.org/10.3390/metabo10100419 |
work_keys_str_mv | AT saorinasia emergingroleofmetabolomicsinovariancancerdiagnosis AT digregorioemanuela emergingroleofmetabolomicsinovariancancerdiagnosis AT miologianmaria emergingroleofmetabolomicsinovariancancerdiagnosis AT steffanagostino emergingroleofmetabolomicsinovariancancerdiagnosis AT coronagiuseppe emergingroleofmetabolomicsinovariancancerdiagnosis |